Ownership and insider activity for Kyverna Therapeutics, Inc. (KYTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
Price
| Price | $6.90 |
| Market Cap | $419M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-27 | CLARK IAN T | A-Award | 5,093 | |
| 2026-05-27 | CLARK IAN T | A-Award | 20,582 | $177K |
| 2026-05-27 | Cohen Fred E | A-Award | 5,093 | |
| 2026-05-27 | Cohen Fred E | A-Award | 20,582 | $177K |
| 2026-05-27 | SEIDENBERG BETH C | A-Award | 5,093 | |
| 2026-05-27 | SEIDENBERG BETH C | A-Award | 20,582 | $177K |
| 2026-05-27 | Shaw Christi | F-InKind | 4,194 | $36K |
| 2026-05-27 | Aktar Mert | A-Award | 5,093 | |
| 2026-05-27 | Aktar Mert | A-Award | 20,582 | $177K |
| 2026-05-18 | Martini Gregory S. | A-Award | 325,000 | $2.8M |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $76.1M | $37.7M | $34.6M | $96.6M | $124.1M |
| Short-term Investments | 0 | $13.6M | $22.9M | $189.4M | $155.2M |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $77.1M | $53.3M | $60.7M | $290.6M | $283.0M |
| Property, Plant & Equipment | $7.8M | $12.4M | $10.6M | $10.7M | $5.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $85.5M | $66.9M | $75.2M | $304.6M | $293.8M |
| Accounts Payable | $773000 | $1.5M | $4.4M | $4.6M | $5.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $15.9M | $12.0M | $19.9M | $33.8M | $36.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | $24.7M |
| Total Liabilities | $131.7M | $140.9M | $26.0M | $38.1M | $61.5M |
| Retained Earnings | -$46.8M | -$75.7M | -$136.0M | -$263.5M | -$424.8M |
| Total Equity | -$46.3M | -$74.0M | $49.2M | $266.6M | $232.3M |
| Total Debt | $5.6M | $10.6M | $9.1M | $8.2M | $29.0M |
| Net Debt | -$70.5M | -$40.8M | -$48.5M | -$277.7M | -$250.2M |
| Working Capital | $61.2M | $41.3M | $40.8M | $256.8M | $246.5M |
Financial Health
| Debt / Equity | 0.20 |
| Current Ratio | 9.06 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 1.13 |
Profitability
| Return on Equity | -81.91% |
| Return on Invested Capital | -80.05% |
| Return on Assets | -69.44% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLO · AVIR · CABA · CAPR · CTNM · EDIT · LXEO
Explore sector: Healthcare · Biotechnology
More sections of KYTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks